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A B S T R A C T   
We describe a simple, non-invasive assay to identify fucosylated-glycoisoform of integrin alpha-3 (ITGA3) 
directly from unprocessed urine. ITGA3 was detected directly from the urine of bladder cancer (BlCa) (n = 13) 
and benign prostatic hyperplasia (BPH) (n = 9) patients with the use of lectins coated on europium-doped- 
nanoparticles (Eu3+-NPs). Lectin Ulex europaeus agglutinin-I (UEA) showed enhanced binding with BlCa- 
derived ITGA3. The evaluation with individual samples showed that a glycovariant ITGA3-UEA assay could 
significantly discriminate BlCa from BPH patients (p = 0.007). The detection of aberrantly fucosylated-isoform of 
ITGA3 from urine can be used to distinguish BlCa from age-matched benign controls in a simple sandwich assay.   
1. Introduction 
Bladder cancer (BlCa) is the second most occurring urological ma-
lignancy after prostate cancer. Currently, the diagnosis and surveillance 
of bladder cancer is dependent on voided urine cytology and direct 
cystoscopic examination of the bladder [1]. Even though cystoscopy and 
cytology are considered as the golden standard investigation, these tests 
have limitations in either sensitivity or specificity [2,3]. Moreover, 
numerous commercially available FDA-approved biomarkers and kits 
for the detection of BlCa have been developed. These include assays 
based on the detection of bladder tumor antigen (BTA) and nuclear 
matrix protein 22 (NMP22). Also, the ImmunoCyt + test, relying on the 
detection of mucins and carcinoembryonic antigen (CEA). Unfortu-
nately, none of them have been accepted for the diagnosis or follow-up 
of BlCa in routine practice due to the limited sensitivities or specificities 
[4]. Thus, there is an urgent need for the development of a non-invasive, 
sensitive, and specific diagnostic tool that could be used for the detec-
tion and follow-up of bladder cancer. 
Integrins are heterodimeric transmembrane proteins consisting of an 
alpha (α) and a beta (β) chain. In mammals, integrins have twenty-four α 
and nine β subunits. Several types of integrins or their parts have also 
been found on the surface of cells and extracellular vesicles [5,6] and as 
soluble proteins which can be detected from urine [7]. Some integrins 
(e.g.-α6β4, α5 and β3) are highly glycosylated and linked with a variety 
of glycan structures [8, 9]. Previously ITGA3 has been shown to contain 
aberrant glycosylations, particularly in BlCa [10]. As such, targeting the 
glycosylation patterns of ITGA3 in BlCa could provide novel tools for 
cancer diagnosis. 
Lectins are a large group of glycan binding proteins with diverse 
structures and origin. Due to their capacity for specific recognition of 
glycan structures they are widely used research tools in glycobiology. 
Ulex europaeus agglutinin-I (UEA), with a molecular weight of 63 kDa, is 
a plant lectin having affinity to various fucosylated glycans, particularly 
for structures containing Fucα1-2Galβ moiety [11]. UEA and other 
fucose-specific lectins such as Aleuria aurantia lectin (AAL; specific for 
fucα1-6/3GlcNAc) [12] have previously been reported for the detection 
of the fucosylation status of prostate specific antigen (PSA) in prostate 
cancer [13, 14]. The strength of lectin-glycan interaction is usually 
relatively weaker for example in comparison to typical antibody-antigen 
interactions [15]. However, it has been shown that the problem of low 
affinity of lectins can be compensated with the avidity effect when 
coated on nanoparticles (NPs) [16, 17]. We previously demonstrated 
that the use of macrophage galactose lectin when conjugated on Eu-NPs, 
enhances the cancer specificity of a conventional CA125 assay used for 
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the detection of ovarian cancer (OvCa) [18]. In the present study, we 
report the detection of ITGA3 glycoisoform with the use of UEA conju-
gated on nanoparticles. The assay is capable of discriminating BlCa from 
clinically challenging age-matched benign conditions directly from un-
processed urine. 
2. Materials and methods 
2.1. Urine samples 
This study was conducted with the approval of the Ghent University 
Hospital ethics committee (B670201420715) and in accordance with 
the guidelines and regulations of the Helsinki Declaration. Participants 
had given written informed consent. Urine samples from patients with 
bladder cancer (n = 13) were collected by catheterization prior to sur-
gical treatment by transurethral resection of the bladder tumor (TURBT) 
or radical cystectomy. Similarly, age matched urine samples from with 
benign prostatic hyperplasia (BPH) patients (n = 9) were collected prior 
to transurethral resection of the prostate (TURP) or simple prostatec-
tomy and used as control. All patients were in a fasting state. Patients 
characteristics are presented in Table 1. Both bladder and non-bladder 
cancer samples were histologically classified and urological co- 
morbidities possibly influencing immunoassay results were listed 
(Supplementary Table 1). Urine samples were stored at − 80 ◦C until use. 
Prior to the assay, urine samples were thawed at room temperature and 
centrifuged at 2000 g for 5 min to remove cells and cell debris. 
2.2. Conjugation nanoparticles with lectins 
An overview of the lectins tested in this study, and their major 
glycan-binding specificities is provided in supplementary Table 2. Lec-
tins were coated on Eu3+-NPs, as previously described with minor 
modifications [17]. In brief, Eu3+-NPs (Seradyn Indianapolis IN, USA) 
are monodispersed polystyrene beads that produce long-life time fluo-
rescence. Approximately 1 × 1012 Eu3+-NPs were used per reaction. The 
lectins, through their amino groups, were covalently coupled with 
activated carboxyl groups present on the Eu3+-NPs. Concentration of 
lectins was 0.1 mg/mL in the coupling reaction. The surface of the 
nanoparticles was activated with 8 mmol/L NHS and 1.3 mmol/L EDC 
(Sigma-Aldrich, St. Louis, Mo, USA). Then, lectins were coupled with 
activated particles by vortexing for 30 min in MES buffer (50 mM, pH 
6.1, 100 mM NaCl). Bovine serum albumin (BSA), with a final concen-
tration 10 mg/mL, was added in the reaction-mixture, followed by 
vortexing for 30 min, to block remaining active sites on the particles. 
Next, the reaction-mixture was incubated at +4 ◦C overnight in a rotary 
mixer. The following day, the mixture was concentrated using a Nanosep 
centrifugal filter device (300 K) at 6000 g and washed again in storage 
buffer (25 mM Tris, pH 7.8, 150 mM NaCl, 0.1% NaN3). The bio-
conjugated NPs were recovered in storage buffer and stored at +4 ◦C by 
adding BSA (with a final concentration of 2 mg/mL) for two days in 
order to remove the aggregates. After sonication with Vail Tweeter (7 
pulses, 0.5 cycle, amplitude 100%) and centrifugation (500 g, 5 min), 
the aggregate-free supernatant was collected and stored at +4 ◦C until 
use. 
2.3. Capture-antibody labeling with biotin 
Following antibody was used for immunocapturing: monoclonal 
anti-ITGA3 (clone IA3; catalogue number MAB1345, R&D systems, 
Abingdon, UK). Antibody was biotinylated as described previously, with 
minor modifications [17,18]. Briefly, the pH of the antibody solution 
was adjusted to 9.8 with 0.5 M of carbonate buffer. Biotin isothiocyanate 
(BITC) was dissolved in absolute ethanol to a final concentration of 10 
mM. A 40-fold excess of biotin to antibody was added to the final re-
action volume (antibody concentration: ~2 mg/mL). After 4 h incuba-
tion at RT, unreacted BITC was removed by gel filtration with NAP-5 
columns using TSA buffer (pH 7.5, 50 mmol/L Tris-HCL, 150 mmol/L 
NaCl, and 0.5 g/L NaN3). Then, biotinylated antibodies were stored at 
+4 ◦C in 1 g/L BSA. 
2.4. Immunoassay 
The schematic representation of the time-resolved fluorescence 
(TRF) immunoassay is displayed in Fig. 1. Briefly, 150 ng of biotinylated 
capture antibody (anti-ITGA3) was diluted in assay buffer (Kaivogen, 
Turku, Finland) in a final volume of 30 μL/well and immobilized in a 96- 
wells-streptavidin-coated plate (KaiSA96, Kaivogen, Turku, Finland) for 
1 h at RT, followed by washing of the wells 4 times with wash buffer 
(Kaivogen, Turku, Finland). Then, 50 μL of urine sample and 100 μL of 
assay buffer were added to each well. After 1 h incubation at RT on a 
plate shaker at 600 rpm, the wells were washed 4 times with wash 
buffer. Altered glycosylation on the captured glycoproteins was detected 
using lectin conjugated Eu3+-NPs (lectin-NPs). In a final volume of 30 
μL, 1 × 107 of lectin-NPs were added to each well and incubated for 1.5 h 
at RT on a plate shaker with slow shaking. Next, the wells were washed 4 
times with wash buffer in a DELFIA plate washer. Signal measurement 
was performed (λex: 340 nm; λem: 615 nm) with a Victor™ 1420 mul-
tilabel counter (PerkinElmer) using the program europium from surface. 
All measurements were conducted in triplicate and signal/background 
was picked up for analysis. 
2.5. Data analysis 
Statistical analysis was performed using GraphPad Prism software, 
lnc (version 6). Comparison of medians was performed using a Man-
n–Whitney rank sum test. Contingency tables were analyzed using a 
Fisher’s exact test. A two-tailed P value < 0.05 indicated statistical 
significance. 
Table 1 
Patient and tumor characteristics. Abbreviations: TURBT: transurethral resec-
tion of bladder tumor; TURP: transurethral resection of the prostate.  
Patients 
characteristics 
Bladder Cancer (n 
= 13) 
Benign Prostatic 





70 (54–80) 73 (58–85) 0.37 
Sex, n (%) 
Male 10 (76.9%) 9 (100%) 0.24 
Female 3 (23.1%) 0 (0%) 
Tumor stage, n (%) 
Ta 2 (15.4%)   
Tis 2 (15.4%)   
T1 1 (7.7%)   
T2 2 (15.4%)   
T3 4 (16.7%)   
T4 2 (30.8%)   
Tumor grade, n (%)  
Low grade 0 (0%)   
High grade 13 (100%)   
Nodal stage, n (%)    
N0 9 (69.2%)   
N1 2 (15.4%)   
N2 2 (15.4%)   
Neo-adjuvant chemotherapy, n (%) 
Yes 3 (23.1%)   
No 10 (76.9%)   
Local treatment, n (%) 
TURBT 2 (15.4%)   
Radical cystectomy 11 (84.6%)   
TURP  4 (44.4%)  
Simple 
prostatectomy  
5 (55.6%)  
Urological comorbidity, n (%) 
Yes 2 (15.4%) 3 (33.3%)  
No 11 (84.6%) 6 (66.7%) 0.61  
Md.K. Islam et al.                                                                                                                                                                                                                               
Analytical Biochemistry 628 (2021) 114283
3
3. Results 
3.1. Glycoprofiling with Lectin-NPs 
To explore if particular glycosylations of ITGA3 differ between the 
two patient groups, we used a time-resolved-fluorometry sandwich 
bioaffinity-assay with 9 different lectins (UEA, AAL, SBA, SNA, GSL-1, 
DC-SIGN, WGA, BPL, and DSL) coated on Eu3+-doped nanoparticles. 
With the use of pooled urine samples (benign n = 9, BlCa n = 13), we 
observed distinct binding intensities for different lectins on immuno-
captured urinary ITGA3 (Fig. 2). We also detected the total ITGA3 with 
the use of an assay combining an anti-ITGA3 antibody as both capture 
and tracer (ITGA3-ITGA3). The total ITGA3 showed a 2-fold higher 
signal-to-background (S/B) ratio in pooled BlCa compared to benign 
samples, whereas the ITGA3 assay with lectin UEA as a tracer (ITGA3- 
UEA) showed over 6-fold higher S/B ratio (Fig. 2). ITGA3 assays con-
structed with five other lectin-NPs (AAL, SNA, GSL-1, DC-SIGN, and 
BPL) showed 2-, 2-, 2-, 1.5-, and 3-fold higher S/B ratios, respectively. 
The remaining three lectin-NPs (SBA, WGA, and DSL) showed no 
discrimination between pooled BlCa compared to benign samples. 
3.2. Detection of bladder cancer with ITGA3-UEA assay 
Next, the performance of the ITGA3-UEA assay was evaluated with 
the use of individual urine samples from BlCa patients and patients with 
the benign condition BPH. The performance of the ITGA3-ITGA3 assay 
was also studied with the corresponding samples. The difference be-
tween both groups was considered statistically significant when the two- 
tailed P value < 0.05. Both the total ITGA3-ITGA3 and the ITGA3-UEA 
assay showed statistically significant discrimination between sample 
groups (Fig. 3). However, the discrimination was clearly more distinct in 
the case of ITGA3-UEA assay as indicated e.g., by the difference between 
median values of BlCa and BPH samples being 4.8 and 2.8-fold for the 
ITGA3-UEA and ITGA3-ITGA3 assay, respectively. 
Fig. 1. Schematic representation of assay: Biotinylated antibody (anti-ITGA3) was immobilized on the surface of streptavidin coated microtiter wells to capture 
ITGA3 from urine samples. The captured ITGA3 was detected with Eu3+-doped polystyrene nanoparticles conjugated either with (a) anti-ITGA3 antibody or (b) 
lectins. This figure was created using BioRender.com (2020). 
Fig. 2. Screening of different lectin-NPs for the detection of immunocaptured 
ITGA3 antigen from pooled urine samples of BPH and BlCa patients. The levels 
of total ITGA3 (blue box) as detected with Eu-NPs coated with anti-ITGA3 
antibody tracer are also shown. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the Web version of this article.) 
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4. Discussion 
In this study, we describe a simple, lectin-based detection of aberrant 
glycosylation on ITGA3 as a potential tool for the discrimination of BlCa 
from benign urological conditions like BPH. 
ITGA3, which has previously been reported to be overexpressed in 
cancer [17], was used as a starting point for the assay. With the use of 
various lectin-NPs, we investigated what kind of glycovariants of ITGA3 
could be used to increase the cancer specificity of the assay. Among the 
lectins, we found UEA in combination with ITGA3 (ITGA3-UEA) to have 
significantly higher S/B ratio of pooled BlCa samples compared to 
pooled BPH samples. The ITGA3-UEA assay was further evaluated using 
individual urine samples from BlCa and BPH patients. To confirm that 
the enhanced cancer specificity was in fact a result of changes in the 
glycosylations, we also performed an assay where the total ITGA3 was 
detected using anti-ITGA3 antibody both as a capture and a tracer 
(Fig. 3a). This same approach to detect a membrane associated protein 
with the same monoclonal capture antibody has previously been used to 
detect extracellular vesicles and exosomes from various biofluids [19]. 
Although the full characterization whether ITGA3 is on EVs was out of 
the scope of this study, integrins have previously been reported to be 
found on EVs by several studies [20–22]. 
UEA has previously been characterized to have specificity towards 
fucosylated glycans, particularly Fucα1-2Galβ. The fucosylation changes 
found on ITGA3 are to some extent in line with characterized epitopes 
found using monoclonal antibodies [23]. Although the previously 
characterized epitope also consist of fucosylated glycans, the main 
glycan moiety was found to be Lewis x antigen (Galβ1-4(Fucα1-3) 
GlcNAc). Although the specific structures and particularly the mecha-
nism leading to the fucose changes in bladder cancer remains elusive, 
targeting fucosylations in diagnosis holds great promise both in diag-
nosis and treatment of BlCa [24]. 
By combining ITGA3 capture and the detection of fucosylated gly-
cans with UEA, we were able to significantly (p = 0.007) discriminate 
BlCa from BPH (Fig. 3b). This ITGA3-UEA-NP assay shows promise in 
the non-invasive detection of bladder cancer directly from unprocessed 
urine samples and calls for further studies with a larger patient cohort. 
The assay concept can also be easily modified by explore the biomarker 
potential of other bladder cancer associated glycoproteins. 
5. Conclusion 
We developed an assay combining immunocapture of urinary 
integrin and the detection of fucosylated glycans on the integrin with the 
use of lectins. This assay can be used to non-invasively discriminate BlCa 
from benign conditions with no preanalytical processing of the samples. 
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